28.84USD+1.51%Mkt Cap: 1.28B USDP/E: —Last update: 2026-05-22
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company pr…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.28B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-85.20M USD
Revenue/Share—
Last Price28.84 USD
Fiscal Year EndDec 2025
MR Quarter—
Employees50
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-2.81
EPS (TTM)-2.04
EPS (Forward)—
52W Range
25.0553% of range32.23
52W High32.23 USD
52W Low25.05 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE35.70%
ROA-57.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.48M USD
CapEx (TTM)344.00K USD
FCF Margin—
FCF Yield-3.96%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.01
Current Ratio10.19
Quick Ratio9.86
Book Value/Sh-10.1070 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.31M
Float14.45M
Insiders0.00%
Institutions52.92%
Short Interest
Short Ratio0.0d
Short % Float0.00%
Short % Out.0.00%
Shares Short0
Technical
SMA 5028.73 (+0.4%)
SMA 20028.73 (+0.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)735.03K
Avg Vol (10d)266.67K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—